Watch out, Dupixent. Pfizer’s new JAK inhibitor could come after your eczema market
New Biktarvy spot puts Gilead in top TV-spending ranks, right behind AbbVie and Pfizer
Can Pfizer get Xeljanz, Xtandi pumping while it waits for pipeline help?
Does Pfizer’s Xeljanz share its CV safety questions with burgeoning JAK class?
Drugmakers vie to capture slice of rheumatoid arthritis market
Viagra no more: The changing face of drug ads on TV
Pharma TV buys so far top last year’s $1B spend; AbbVie, Pfizer lead September
Έγκριση του tofacitinib citrate στην Ευρώπη για την ελκώδη κολίτιδα
Pfizer reported its second-quarter financials, with adjusted earnings per share coming in at $0.81, exceeding the consensus forecast of $0.74, up 20.9 percent from the same period in 2017. The company’s revenues were $13.47 … Continue Reading Pfizer’s Q2 Earnings Exceed Expectations